{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:33:26Z","timestamp":1767990806900,"version":"3.49.0"},"reference-count":23,"publisher":"American Psychiatric Association Publishing","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AJP"],"published-print":{"date-parts":[[2003,4,1]]},"DOI":"10.1176\/appi.ajp.160.4.741","type":"journal-article","created":{"date-parts":[[2003,3,31]],"date-time":"2003-03-31T19:10:12Z","timestamp":1049137812000},"page":"741-748","source":"Crossref","is-referenced-by-count":277,"title":["Ziprasidone in the Treatment of Acute Bipolar Mania: A Three-Week, Placebo-Controlled, Double-Blind, Randomized Trial"],"prefix":"10.1176","volume":"160","author":[{"suffix":"Jr.","given":"Paul E.","family":"Keck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcio","family":"Versiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Potkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott A.","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Earl","family":"Giller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Ice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Ziprasidone in Mania Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"230","reference":[{"key":"R1604CHHGEEHG","doi-asserted-by":"crossref","unstructured":"Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG, Garza-Trevino ES, Risch SC, Goodnick PJ, Morris DD (Depakote Mania Study Group): Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994; 271:918-924","DOI":"10.1001\/jama.271.12.918"},{"key":"R1604CHHBDBFJ","doi-asserted-by":"crossref","unstructured":"Pope HG Jr, McElroy SL, Keck PE Jr, Hudson JI: Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry 1991; 48:62-68","DOI":"10.1001\/archpsyc.1991.01810250064008"},{"key":"R1604CHHHIGBA","doi-asserted-by":"crossref","unstructured":"Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KNR, Daniel DG, Petty F, Centorrino F, Wang R, Grundy SL, Greaney MG, Jacobs TG, David SR, Toma V (Olanzapine HGEH Study Group): Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999; 156:702-709","DOI":"10.1176\/ajp.156.5.702"},{"key":"R1604CHHGEFGA","doi-asserted-by":"crossref","unstructured":"Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, Francis J, Tollefson GD, Breier A (Olanzapine HGGW Study Group): Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2000; 57:841-849","DOI":"10.1001\/archpsyc.57.9.841"},{"key":"atypb1","doi-asserted-by":"crossref","unstructured":"Goodwin FK, Murphy DL, Bunney WE Jr: Lithium-carbonate treatment in depression and mania: a longitudinal double-blind study. Arch Gen Psychiatry 1969; 21:486-496","DOI":"10.1001\/archpsyc.1969.01740220102012"},{"key":"atypb2","doi-asserted-by":"crossref","unstructured":"Maggs R: Treatment of manic illness with lithium carbonate. Br J Psychiatry 1963; 109:56-65","DOI":"10.1192\/bjp.109.458.56"},{"key":"atypb3","doi-asserted-by":"crossref","unstructured":"Schon M, Juel-Nielson N, Stromgren E, Voldby H: The treatment of manic psychoses by administration of lithium salts. J Neurol Neurosurg Psychiatry 1954; 17:250-260","DOI":"10.1136\/jnnp.17.4.250"},{"key":"R1604CHHDABFG","doi-asserted-by":"crossref","unstructured":"Stokes PE, Shamoian CA, Stoll PM, Patton MJ: Efficacy of lithium as acute treatment of manic-depressive illness. Lancet 1971; 1:1319-1325","DOI":"10.1016\/S0140-6736(71)91886-1"},{"key":"R1604CHHJGEJI","unstructured":"Ballenger JC, Post RM: Therapeutic effects of carbamazepine in affective illness: a preliminary report. Commun Psychopharmacol 1978; 2:159-175"},{"key":"R1604CHHCJFDE","doi-asserted-by":"crossref","unstructured":"Klein DF: Importance of psychiatric diagnosis in prediction of clinical drug effects. Arch Gen Psychiatry 1967; 16:118-126","DOI":"10.1001\/archpsyc.1967.01730190120016"},{"key":"R1604CHHIBHDH","doi-asserted-by":"crossref","unstructured":"Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH: Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001; 425:197-201","DOI":"10.1016\/S0014-2999(01)01188-8"},{"key":"R1604CHHFEDHE","doi-asserted-by":"crossref","unstructured":"Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M (Ziprasidone Study Group): Ziprasidone 80 mg\/day and 160 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999; 20:491-505","DOI":"10.1016\/S0893-133X(98)00090-6"},{"key":"atypb4","doi-asserted-by":"crossref","unstructured":"Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR: Ziprasidone 40 and 120 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 1998; 140:173-184","DOI":"10.1007\/s002130050755"},{"key":"R1604CHHHCJCC","doi-asserted-by":"crossref","unstructured":"Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, Wilner KD, Law CG, Ko GN: An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998; 18:296-304","DOI":"10.1097\/00004714-199808000-00009"},{"key":"R1604CHHEJGAF","doi-asserted-by":"crossref","unstructured":"Keck PE Jr, Reeves KR, Harrigan EP: Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol 2001; 21:27-35","DOI":"10.1097\/00004714-200102000-00007"},{"key":"R1604CHHBBHDJ","doi-asserted-by":"crossref","unstructured":"Davis R, Markham A: Ziprasidone. CNS Drugs 1997; 8:153-159","DOI":"10.2165\/00023210-199708020-00006"},{"key":"R1604CHHJAIJC","doi-asserted-by":"crossref","unstructured":"Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156:1686-1696","DOI":"10.1176\/ajp.156.11.1686"},{"key":"R1604CHHFAJCG","doi-asserted-by":"crossref","unstructured":"Endicott J, Spitzer RL: A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry 1978; 35:837-844","DOI":"10.1001\/archpsyc.1978.01770310043002"},{"key":"R1604CHHGEJGJ","unstructured":"Metropolitan Life Insurance Company: 1983 Metropolitan height and weight tables. Stat Bull Metrop Life Found 1983; 64:3-9"},{"key":"R1604CHHHCHAB","doi-asserted-by":"crossref","unstructured":"Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276","DOI":"10.1093\/schbul\/13.2.261"},{"key":"R1604CHHHCIAE","doi-asserted-by":"crossref","unstructured":"Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"R1604CHHGAAGG","doi-asserted-by":"crossref","unstructured":"Barnes TRE: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676","DOI":"10.1192\/bjp.154.5.672"},{"key":"atypb5","doi-asserted-by":"crossref","unstructured":"Meltzer HY, McGurk SR: The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999; 25:233-255","DOI":"10.1093\/oxfordjournals.schbul.a033376"}],"container-title":["American Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.160.4.741","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T09:53:45Z","timestamp":1722419625000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.160.4.741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4,1]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,4,1]]}},"alternative-id":["10.1176\/appi.ajp.160.4.741"],"URL":"https:\/\/doi.org\/10.1176\/appi.ajp.160.4.741","relation":{},"ISSN":["0002-953X","1535-7228"],"issn-type":[{"value":"0002-953X","type":"print"},{"value":"1535-7228","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,4,1]]}}}